Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.

Autor:	Friedberg JW; Wilmot Cancer Institute, University of Rochester, Rochester, NY., Bordoni R; Georgia Cancer Specialists, Marietta, GA., Patel-Donnelly D; Virginia Cancer Specialists, Fairfax, VA., Larson T; Minnesota Oncology PA, Minneapolis, MN., Goldschmidt J; Oncology and Hematology Associates of SW Virginia, Blacksburg, VA., Boccia R; Center for Cancer and Blood Disorders, Bethesda, MD., Cline VJM; Texas Oncology, Austin, TX., Mamidipalli A; Seagen Inc, Bothell, WA., Liu J; Seagen Inc, Bothell, WA., Akyol A; Bristol Myers Squibb, Princeton, NJ., Yasenchak CA; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2024 Feb 29; Vol. 143 (9), pp. 786-795.
DOI:	10.1182/blood.2022019536
Abstrakt:	Abstract: Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have inferior outcomes compared with younger patients, potentially due to comorbidities and frailty. This noncomparative phase 2 study enrolled patients aged ≥60 years with cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (part B) or nivolumab (part D; 3 mg/kg). In parts B and D, 50% and 38% of patients, respectively, had ≥3 general comorbidities or ≥1 significant comorbidity. Of the 22 patients treated with BV-DTIC, 95% achieved objective response, and 64% achieved complete response (CR). With a median follow-up of 63.6 months, median duration of response (mDOR) was 46.0 months. Median progression-free survival (mPFS) was 47.2 months; median overall survival (mOS) was not reached. Of 21 patients treated with BV-nivolumab, 86% achieved objective response, and 67% achieved CR. With 51.6 months of median follow-up, mDOR, mPFS, and mOS were not reached. Ten patients (45%) with BV-DTIC and 16 patients (76%) with BV-nivolumab experienced grade ≥3 treatment-emergent adverse events; sensory peripheral neuropathy (PN; 27%) and neutropenia (9%) were most common with BV-DTIC, and increased lipase (24%), motor PN (19%), and sensory PN (19%) were most common with BV-nivolumab. Despite high median age, inclusion of patients aged ≤88 years, and frailty, these results demonstrate safety and promising durable efficacy of BV-DTIC and BV-nivolumab combinations as frontline treatment, suggesting potential alternatives for older patients with cHL unfit for initial conventional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01716806. (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu